Progress in the development of human parainfluenza virus vaccines

Alexander C. Schmidt, Anne Schaap-Nutt, Emmalene J. Bartlett, Henrick Schomacker, Jim Boonyaratanakornkit, Ruth A. Karron, Peter L. Collins

Research output: Contribution to journalReview articlepeer-review


In children under 5 years of age, human parainfluenza viruses (HPIVs) as a group are the second most common etiology of acute respiratory illness leading to hospitalization, surpassed only by respiratory syncytial virus but ahead of influenza viruses. Using reverse genetics systems for HPIV serotypes 1, 2 and 3 (HPIV1, 2 and 3), several live-attenuated HPIVs have been generated and evaluated as intranasal vaccines in adults and in children. Two vaccines against HPIV3 were found to be well tolerated, infectious and immunogenic in Phase I trials in HPIV3-seronegative infants and children and should progress to proof-of-concept trials. Vaccines against HPIV1 and HPIV2 are less advanced and have just entered pediatric trials.

Original languageEnglish (US)
Pages (from-to)515-526
Number of pages12
JournalExpert review of respiratory medicine
Issue number4
StatePublished - Aug 2011


  • acute respiratory illness
  • clinical trial
  • intranasal
  • live-attenuated
  • parainfluenza virus vaccine
  • pediatric
  • vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Progress in the development of human parainfluenza virus vaccines'. Together they form a unique fingerprint.

Cite this